Aarey Drugs & Pharmaceuticals Ltd (AAREYDRUGS) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Aarey Drugs & Pharmaceuticals Ltd on NSE and BSE, with an AI summary of each filing.
Revised outcome
Revision of outcome · 07 Oct 2026, 8:30 pm
Aarey Drugs Approves Allotment of 1.15 Million Shares on Warrant Conversion Aarey Drugs & Pharmaceuticals' board approved the allotment of 1.15 million equity shares of face value Rs. 10 each on 30th Sep'26 upon conversion of preferential warrants. The conversion occurred at an issue price of Rs. 63.80 per warrant (premium of Rs. 53.80) following the receipt of Rs. 47.85 per warrant (75% balance), aggregating to Rs. 55.03 million. Consequently, total paid-up equity expanded to 31.87 million shares (Rs. 318.74 million), with 1.48 million warrants remaining outstanding for conversion out of the original 5.0 million issued.
Scrutinizers Report of 36th Annual General Meeting
Annual General Meeting · 06 Oct 2026, 1:31 am
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nimit Rajesh Ghatalia
Acquisition/ Disposal of Shares · 05 Oct 2026, 5:05 pm
Aarey Drugs & Pharmaceuticals Promoter Group Converts Warrants to Expand Equity Stake Aarey Drugs & Pharmaceuticals Limited disclosed the allotment of equity shares to its promoter and promoter group following warrant conversions finalized on 30th Sep'26. Total promoter group holding increased to 13,212,443 equity shares, representing 41.45% of total share capital (39.91% diluted), up from 10,692,442 shares (37.71%). Key allotments include conversions by Bina Rajesh Ghatalia (500,000 warrants), Nimit Rajesh Ghatalia (500,000 warrants), Mihir Rajesh Ghatalia (345,000 warrants), and Ekta Nimit Ghatalia (500,000 warrants), expanding the company's total voting capital to 31,874,303 equity shares.
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nimit Rajesh Ghatalia
Acquisition/ Disposal of Shares · 05 Oct 2026, 4:22 pm
Nimit Rajesh Ghatalia Increases Stake in Aarey Drugs & Pharmaceuticals to 5.18% Nimit Rajesh Ghatalia acquired 150,000 equity shares (0.47% voting capital) of Aarey Drugs & Pharmaceuticals Ltd on 30th Sep'26 through warrant conversion. The non-promoter acquirer previously held 1,500,000 shares (4.88%) alongside 150,000 convertible warrants (0.49%). Post-allotment, total equity shareholding stands at 1,650,000 shares, representing 5.18% of total voting capital and 4.94% on a fully diluted basis. Following the conversion, the company's total voting capital increased from 30,724,303 to 31,874,303 equity shares of Rs. 10 each, with diluted capital at 33,354,303 shares.
DISCLOSURE AS PER SEBI SAST REG 29(1) REG 2011
Others (Uncategorized) · 03 Oct 2026, 11:38 pm
Nimit Rajesh Ghatalia Increases Stake in Aarey Drugs via Warrant Conversion Nimit Rajesh Ghatalia was allotted 1,50,000 equity shares of Aarey Drugs & Pharmaceuticals Ltd on 30th Sep'26 following the conversion of warrants. The acquisition represents 0.47% of total voting capital (0.45% diluted). Post-allotment, Ghatalia's total shareholding increased from 15,00,000 shares (4.88%) to 16,50,000 equity shares, representing 5.18% of total voting capital (4.94% diluted). Following the allotment, the company's total equity voting capital expanded to 3,18,74,303 shares of Rs. 10 each, with fully diluted share capital standing at 3,33,54,303 shares.
DISCLOSURE UNDER SEBI SAST REG 29(2) REG 2011
Others (Uncategorized) · 03 Oct 2026, 11:34 pm
Aarey Drugs & Pharmaceuticals Promoters Acquire Equity via Warrant Conversion Aarey Drugs & Pharmaceuticals Limited disclosed an allotment of equity shares to its promoter and promoter group pursuant to warrant conversions as on 30th Sep'26. Total promoter group holding reached 1,32,12,443 equity shares (41.45% of total voting capital and 39.91% on a diluted basis). Key individual post-allotment holdings include Bina Rajesh Ghatalia at 14.13% (45,03,584 shares), Mihir Rajesh Ghatalia at 9.98% (31,80,888 shares), and Nimit Rajesh Ghatalia at 5.18% (16,50,000 shares). Total voting equity expanded to 3,18,74,303 shares post-allotment.
Disclosure under SEBI PIT Reg. 2015
Others (Uncategorized) · 03 Oct 2026, 11:32 pm
Aarey Drugs & Pharmaceuticals Allots Equity Shares on Warrant Conversion Aarey Drugs & Pharmaceuticals Limited disclosed an allotment of equity shares on 30th Sep'26 following the conversion of warrants to its promoter and promoter group. The transaction involved key promoters, including Bina Rajesh Ghatalia (5,00,000 shares; post-holding 14.13%), Mihir Rajesh Ghatalia (3,45,000 shares; post-holding 9.98%), Nimit Rajesh Ghatalia (5,00,000 shares; post-holding 5.18%), Ekta Nimit Ghatalia (5,00,000 shares; post-holding 1.57%), and others, with formal intimation filed under SEBI (PIT) Regulations on 3rd Oct'26.
AGM Proceedings of 36th Annual General Meeting
Annual General Meeting · 30 Sept 2026, 11:54 pm
Aarey Drugs & Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 06, 2026.
Outcome · 30 Sept 2026, 10:22 pm
Revised Outcome of Board Meeting dated 06-08-2026 approved in Board Meeting 30-09-2026
Outcome · 30 Sept 2026, 8:36 pm
Aarey Drugs & Pharmaceuticals Allots 1.15M Equity Shares on Warrant Conversion Aarey Drugs & Pharmaceuticals approved the allotment of 11,50,000 equity shares of face value Rs. 10 each on 30th Sep'26, pursuant to the conversion of warrants issued at Rs. 63.80 each. The company received Rs. 47.85 per warrant (75% balance payment), aggregating Rs. 5.50 cr from promoter and non-promoter allottees. Consequently, paid-up equity capital increased from Rs. 30.72 cr (3,07,24,303 shares) to Rs. 31.87 cr (3,18,74,303 shares). Out of 50,00,000 total warrants originally issued, 14,80,000 remain outstanding for conversion within 18 months from 23rd May'25.
OUTCOME OF BOARD MEETING HELD ON 30-09-2026
Others (Uncategorized) · 30 Sept 2026, 8:24 pm
Aarey Drugs Approves Allotment of 1.15 Million Equity Shares on Warrant Conversion Aarey Drugs & Pharmaceuticals approved the allotment of 11,50,000 equity shares of face value Rs. 10 each on 30th Sep'26 upon conversion of fully convertible warrants at an issue price of Rs. 63.80 per warrant. The company received Rs. 47.85 per warrant (75% balance payment), aggregating to Rs. 5.50 crore from promoter and non-promoter allottees. Consequently, the issued and paid-up capital expanded to Rs. 31.87 crore comprising 3,18,74,303 equity shares. A total of 14,80,000 convertible warrants remain outstanding for conversion within 18 months from 23rd May'25.
Disclosure Under Regulation 30of SEBI(Listing Obligation And Disclosure Requirement ) Regulation, 2015
Others (Uncategorized) · 12 Sept 2026, 1:02 am
Aarey Drugs Schedules 36th AGM for 30th Sep'26 Aarey Drugs & Pharmaceuticals Ltd has scheduled its 36th Annual General Meeting (AGM) for 30th Sep'26 at 3:00 PM IST via Video Conferencing / Other Audio Visual Means. In compliance with SEBI LODR Regulation 36(1)(b), the company issued web-link access notices for its FY25-26 Annual Report to shareholders without registered email IDs as of the 4th Sep'26 cut-off date. The report is accessible via the company's investor portal.
Notice and Integrated Annual Report for 36TH Annual General Meeting of Company as required under Regulation 34(1)
Others (Uncategorized) · 09 Sept 2026, 2:11 am
Notice of 36th Annual General Meeting of the Company for the FY 2025-26
Annual General Meeting · 09 Sept 2026, 2:01 am
Aarey Drugs & Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on September 05, 2026.
Outcome · 06 Sept 2026, 1:33 am
Aarey Drugs & Pharmaceuticals Approves 36th AGM Notice and FY26 Annual Report Aarey Drugs & Pharmaceuticals announced that its Board of Directors approved the draft Board Report, FY26 Annual Report, and the notice convening the company's 36th Annual General Meeting (AGM). The AGM is scheduled for 30th Sep'26 at 3:00 PM IST via Video Conferencing/OAVM. Additionally, the Board approved the book closure dates, cut-off date for e-voting, and appointed Practicing Company Secretary Virendra G. Bhatt (COP No. 124) as the scrutinizer for the AGM e-voting process.
As per attachment
Others (Uncategorized) · 06 Sept 2026, 1:26 am
Aarey Drugs & Pharmaceuticals Approves 36th AGM Notice and Related Filings The Board of Directors of Aarey Drugs & Pharmaceuticals approved the draft Board Report, Annual Report, and notice to convene the 36th Annual General Meeting (AGM) for FY26 on 5th Sep'26. The 36th AGM is scheduled for 30th Sep'26 at 3:00 PM IST via Video Conferencing/OAVM. Additionally, the board approved the book closure dates, the e-voting cut-off date, and the appointment of Practicing Company Secretary Virendra G. Bhatt as the scrutinizer for the AGM e-voting process.
As per Attachment
Financial Result · 15 Aug 2026, 2:08 am
Aarey Drugs Q1FY27: Revenue Declines While Profit Holds Steady QoQ Aarey Drugs reported weak Q1FY27 results, with revenue from operations at ₹44.6cr, a significant decline of 56.3% YoY and 76.4% QoQ. Despite the sharp revenue fall, Profit After Tax (PAT) remained relatively stable sequentially at ₹1.02cr (vs. ₹1.00cr QoQ), though it was down 25.4% YoY from ₹1.37cr. The company operates in a single segment. A statement on the utilization of funds from convertible warrants issued in May'25 confirmed no further funds were received during the quarter ended 30th Jun'26.
Outcome of Board Meeting held on friday, 14th August, 2026
Outcome · 15 Aug 2026, 1:58 am
Aarey Drugs & Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakhs) ■ Revenue: 4,463 (-56.3% YoY | -76.4% QoQ) ■ EBITDA: 133 (-22.2% YoY | -69.5% QoQ) ■ EBITDA Margin (%): 3.0 (+130 bps YoY | +68 bps QoQ) ■ PAT: 102 (-25.3% YoY | +2.1% QoQ) ■ EPS (INR): 0.36 (-25.0% YoY | +2.9% QoQ)
Aarey Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve This is to intimate ....
Intimation · 14 Aug 2026, 5:30 am
Aarey Drugs Board Meeting on 14th Aug'26 to Approve Q1 Results Aarey Drugs & Pharmaceuticals Ltd. has scheduled a Board of Directors meeting for 14th Aug'26. The key agenda is to consider and approve the Unaudited Financial Results and the Limited Review Report for the quarter ended 30th Jun'26. In compliance with SEBI regulations, the trading window for designated persons has been closed since 1st Jul'26 and will reopen 48 hours after the financial results are declared.
Allotment of Equity Shares Pursuant to Conversion of Warrants
Others (Uncategorized) · 06 Aug 2026, 11:35 pm
Aarey Drugs Allots 2.52 Mn Shares on Warrant Conversion at Rs. 63.80 On 06-Aug-26, Aarey Drugs & Pharmaceuticals approved the allotment of 2,520,000 equity shares (FV Rs. 10) at a price of Rs. 63.80 per share. This action follows the conversion of warrants initially issued on a preferential basis to both promoter and non-promoter groups. The conversion aggregated Rs. 12.06 crore upon receipt of the final 75% payment. Following the allotment, the company's issued and paid-up capital increased from Rs. 28.35 crore to Rs. 33.35 crore. A balance of 2,480,000 warrants remain outstanding for conversion.
as per attachment
Others (Uncategorized) · 31 May 2026, 1:48 am
Aarey Drugs Q4FY26 PAT Jumps 231% YoY to ₹155.74 Lakhs Aarey Drugs & Pharmaceuticals reported a 231.3% YoY rise in Q4FY26 profit after tax to ₹155.74 lakhs. Total income for the quarter grew 63.5% YoY to ₹18,904.29 lakhs. However, for the full year FY26, PAT declined 1.4% to ₹396.76 lakhs, while total income fell 3.1% to ₹47,836.61 lakhs. The board approved the audited standalone financial results for the quarter and year ended 31st Mar'26. The auditor's report contains an unmodified opinion with an Emphasis of Matter on unconfirmed debtor/creditor balances.
As per Attachment
Financial Result · 31 May 2026, 1:18 am
Aarey Drugs Reports Q4FY26 PAT of ₹155.74 Lakhs with Unmodified Audit Opinion Aarey Drugs & Pharmaceuticals reported a Q4FY26 PAT of ₹155.74 lakhs, a significant QoQ increase from ₹56.95 lakhs and YoY from ₹47.01 lakhs. For FY26, total income stood at ₹47,836.61 lakhs, with a PAT of ₹396.76 lakhs versus ₹402.39 lakhs in FY25. The Board approved the audited standalone results for the quarter and year ending 31st Mar’26. The statutory auditors issued an unmodified opinion. There was no deviation in the utilization of ₹797.50 lakhs raised via convertible warrants during the year.
Outcome of Board Meeting held on Saturday, 30th May, 2026
Outcome · 31 May 2026, 1:08 am
Aarey Drugs Q4FY26 PAT Jumps 231% YoY to ₹155.74 Lakhs Aarey Drugs & Pharmaceuticals reported a 231.3% YoY rise in Q4FY26 PAT to ₹155.74 lakhs from ₹47.01 lakhs. Revenue from operations grew 75.3% YoY to ₹18,947.24 lakhs. QoQ, PAT increased by 173.5% while revenue grew 96.5%. For the full year FY26, PAT was ₹396.76 lakhs, a slight decrease from ₹402.39 lakhs in FY25, on revenues of ₹47,226.90 lakhs. The board approved the audited standalone results for the quarter and year ended 31st Mar'26 with an unmodified audit opinion.
Aarey Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve Pursuant to the ....
Intimation · 29 May 2026, 5:30 am
Aarey Drugs & Pharma Board Meeting on 29-May-26 for FY26 Results Aarey Drugs & Pharmaceuticals Ltd. has scheduled a Board of Directors meeting on 29-May-26. The agenda includes the consideration and approval of the audited financial results for the quarter and financial year ended 31-Mar-26. The Trading Window for designated persons is currently closed and will reopen 48 hours after the financial results are announced.
Board Comments on the fine levied by the Exchange
Others (Uncategorized) · 13 Feb 2026, 12:36 am
Aarey Drugs Fined by Exchanges for SEBI Compliance Breach Aarey Drugs & Pharmaceuticals received non-compliance notices from BSE and NSE on 16th Dec'25. The company was fined for delayed submission of related party transaction disclosures for the half-year ended 30th Sep'25, violating SEBI LODR Regulation 23(9). Aarey Drugs has paid a total fine of ₹5,900 to each exchange, consisting of a ₹5,000 penalty plus 18% GST. The board stated the delay was inadvertent and has since submitted the required disclosures, committing to strengthening internal compliance mechanisms to prevent future occurrences.